Free Newsletter
U.K. pharma intensifies self-policing rules
U.S. lawmakers aren't the only ones toughening up on pharma. In the U.K., the industry itself is strengthening its code. The Association of the British Pharmaceutical Industry is adding rules on disclosure--of support for patient organizations, of sponsorships, of donations and grants to institutions that support healthcare and research--and on reporting side effects. Promo materials must "prominently" state that "adverse events should be reported" and offer contact information for those reports. And all clinical trials have to be made public; hiding data would be a violation of the rules. The new code will come into effect July 1.
- read the release from ABPI
- see the Financial Times article
- check out the item at PharmaGossip
Related Article:
Pharma CEOs mull industry "trust deficit"
Comments
Post new comment
Paid Research Reports
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
- Optimizing Lifecycle Management: Maximizing commercial lifespan through label expansion and combination products
- The CRO Market Outlook: Emerging markets, leading players and future trends
- Pharmaceutical Sales Force Effectiveness Strategies
- Commercial Insight: Influenza Vaccines and Antivirals - The pandemic's long-term impact





